Sign In
Buy RCEL
$4.16
-0.0300 (-0.716%)
At Close: Jun 03, 2026
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
04:05pm, Thursday, 19'th Jan 2023
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company le
Avita: Micro-Cap With Big Time Approvals On Near Horizon
09:00am, Saturday, 17'th Dec 2022
Avita has a modest existing business selling its skin regeneration products. Its shares have dropped recently despite several successes with the FDA.
AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference
04:01pm, Monday, 21'st Nov 2022
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio
AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Call Transcript
10:15pm, Thursday, 10'th Nov 2022
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Execut
AVITA Medical to Announce Third Quarter 2022 Financial Results
04:01pm, Thursday, 20'th Oct 2022
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization
AVITA Medical, Inc. (RCEL) CEO Dr. Mike Perry on Q2 2022 Results - Earnings Call Transcript
09:03pm, Thursday, 11'th Aug 2022
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2022 Results Conference Call August 11, 2022 5:00 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Dr. Mike Perry - Chief Execut
AVITA Medical to Announce Second Quarter 2022 Financial Results
04:01pm, Monday, 25'th Jul 2022
VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tec
AVITA Medical, Inc. (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript
10:19pm, Thursday, 12'th May 2022
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Of
AVITA Medical Reports First Quarter 2022 Financial Results
08:14pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and c
AVITA Medical to Announce First Quarter 2022 Financial Results
08:01pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a t
AVITA Medical to Announce First Quarter 2022 Financial Results
04:01pm, Thursday, 28'th Apr 2022
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tec
RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
08:01pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a t
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
08:01pm, Monday, 21'st Mar 2022 GlobeNewswire Inc.
Funds will support completion of the ongoing pivotal clinical trial Funds will support completion of the ongoing pivotal clinical trial
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
12:46pm, Thursday, 03'rd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis
NuCana plc (NASDAQ: NCNA) s
AVITA Medical Inks Supply Pact With Premier For RECELL System
09:44am, Thursday, 03'rd Mar 2022
AVITA Medical Inc (NASDAQ: RCEL) has been awarded a group purchasing agreement with Premier Inc (NASDAQ: PINC) The new agreement allows Premier members, at their discretion, to take advantage of
